Long-term molecular complete remission with IFN-α in Ph+ adult acute lymphoid leukemia patients

Piccaluga, Pierpaolo; Martinelli, Giovanni; Isidori, Alessandro; Malagola, Michele; Rondoni, Michela; Paolini, Stefania; Amabile, Marilina; Iacobucci, Ilaria; Baccarani, Michele; Visani, Giuseppe

doi:10.1038/leu.2008.10

Cited by 9 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, preventing TKI resistance is the goal of achieving durable responses. Combining TKIs with steroids, chemotherapy or a-interferon has shown some efficacy (Vignetti et al, 2007;Boulos et al, 2011;Wassmann et al, 2003;Piccaluga et al, 2008). However, these treatments were accompanied by side effects that decreased their tolerability to patients.…”

Section: Introductionmentioning

confidence: 98%

Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia

Guo

Shan

et al. 2015

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 98%

Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia

Guo

Shan

et al. 2015

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

“…Few pilot studies that examined the effects of concomitant administration of IFNα with TKIs, chemotherapy or SCT in patients with Ph+ ALL have reported encouraging results ( 42 – 44 ); however, larger patients’ cohorts and longer follow-ups are necessary to determine whether IFNα has a useful role in the therapy of Ph+ ALL.…”

Section: Discussionmentioning

confidence: 99%

CDKN2A-independent role of BMI1 in promoting growth and survival of Ph+ acute lymphoblastic leukemia

et al. 2016

Self Cite

View full text Add to dashboard Cite

BMI1 is a key component of the PRC1 complex (polycomb repressive complex-1) required for maintenance of normal and cancer stem cells. Its aberrant expression is detected in chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia (ALL), but no data exist on BMI1 requirement in ALL cells. We show here that BMI1 expression is important for proliferation and survival of Ph+ ALL cells and for leukemogenesis of Ph+ cells in vivo. Levels of BIM, interferon-α (IFNα)-regulated genes, and E2F7 were upregulated in BMI1-silenced cells, suggesting that repressing their expression is important for BMI1 biological effects. Consistent with this hypothesis, we found that: i) downregulation of BIM or E2F7 abrogated apoptosis or rescued, in part, the reduced proliferation and colony formation of BMI1 silenced BV173 cells; ii) BIM/E2F7-double silencing further enhanced colony formation and in vivo leukemogenesis of BMI1-silenced cells; iii) overexpression of BIM and E2F7 mimicked the effect of BMI1 silencing in BV173 and SUP-B15 cells and iv) treatment with IFNα suppressed proliferation and colony formation of Ph+ ALL cells. These studies indicate that the growth-promoting effects of BMI1 in Ph+ ALL cells depend on suppression of multiple pathways and support the use of IFNα in the therapy of Ph+ ALL.

show abstract

“…Results of ASCT for Ph + ALL improved markedly in recent years with more than half of patients being alive and leukemia-free at 2 years [40,42,43]. The role of biologic response modifiers such as α-interferon (α-IFN and interleukin-2) in Ph + ALL is analyzed and it was reported that combination of α-IFN with maintenance chemotherapy and ASCT improves the outcomes in Ph + ALL [44,45].…”

Section: Asct For Acute Lymphocytic Leukemiamentioning

confidence: 99%

Consolidation: Autologous Stem Cell Transplantation in Acute Leukemia

Karadağ¹,

Şahin²,

Saydam³

2021

Acute Leukemias

View full text Add to dashboard Cite

The goal of complete remission (CR) in acute leukemias could be achieved with intensive induction chemotherapy however patients need post remission consolidation strategies such as high-dose chemotherapy, or autologous (ASCT) or allogeneic (allo-SCT) hematopoetic stem cell transplantation for durable response. However, Allo-SCT is getting more attention in last decades because of improvements of conditioning regimens and graft versus host disease (GVHD) prohylaxis strategies and alternatively available donor sources, it is not suitable for all leukemia patients. The patients who would benefit from Allo-SCT or ASCT could be defined more easily by using risk stratification systems and minimal residual disease (MRD) monitoring. ASCT is considered a treatment option even if its use is declining in the world. Herein, we tried to summarize the studies that report the outcomes of ASCT in acute myeloid leukemia (AML) and acute, lymphoblastic leukemia and describe the patients who would be good candidate for ASCT.

show abstract

Long-term molecular complete remission with IFN-α in Ph+ adult acute lymphoid leukemia patients

Cited by 9 publications

References 9 publications

Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia

Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia

CDKN2A-independent role of BMI1 in promoting growth and survival of Ph+ acute lymphoblastic leukemia

Consolidation: Autologous Stem Cell Transplantation in Acute Leukemia

Contact Info

Product

Resources

About